Navitoclax (ABT-263)

目录号：S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中Ki分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格 价格 库存 购买数量  
RMB 3285.53 现货
RMB 975.71 现货
RMB 1631.61 现货
RMB 3016.58 现货
RMB 7950.36 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献37篇：

客户使用该产品的13个实验数据：

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中Ki分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。
靶点
Bcl-xL [1]
(Cell-free assay)		 Bcl-2 [1]
(Cell-free assay)		 Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，Ki分别为0.5, 1和1 nM。[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。[2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M3njeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KzR2lEPTB;MD6wNFY3QSEQvF2= NUnXWnNWW0GQR1XS
MV-4-11 M1n1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nLfmlEPTB;MD6wNVU5PiEQvF2= MVrTRW5ITVJ?
NKM-1 M4TiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHsOJlmUUN3ME2wMlAyPjl7IN88US=> NVTlXoRCW0GQR1XS
ML-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEG5PFMh|ryP NX7tN2dPW0GQR1XS
BV-173 M4S5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEKzNVQh|ryP MojGV2FPT0WU
RS4-11 NWi4VG1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H1UGlEPTB;MD6wNlU5PyEQvF2= M4iwW3NCVkeHUh?=
HL-60 NHP3RW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEK5NFgh|ryP NXHWdHltW0GQR1XS
KY821 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEK5O|Uh|ryP NWezbFdvW0GQR1XS
ECC10 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SzVGlEPTB;MD6wN|c6OiEQvF2= MoXyV2FPT0WU
NCI-H720 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ewfWlEPTB;MD6wOFAyOSEQvF2= NVv0OYx{W0GQR1XS
QIMR-WIL MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXlZXNJUUN3ME2wMlA1Ojh5IN88US=> NH;6coNUSU6JRWK=
KG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULlWW1TUUN3ME2wMlA1PDh4IN88US=> NWiwNXFuW0GQR1XS
TGW NYjicWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMES2N|Mh|ryP NXzjb3JPW0GQR1XS
ATN-1 M1XveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XQPGlEPTB;MD6wOFc{OyEQvF2= NWXxXFZxW0GQR1XS
RH-18 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkexTWM2OD1yLkC2NFQ5KM7:TR?= MWjTRW5ITVJ?
EW-18 M1nRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf4ZVlQUUN3ME2wMlA3QDRzIN88US=> NXLidXdXW0GQR1XS
NB17 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEexNlQh|ryP MY\TRW5ITVJ?
SK-NEP-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\QV4dKSzVyPUCuNFczOTNizszN MliyV2FPT0WU
P12-ICHIKAWA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnxTWM2OD1yLkC3O|c5KM7:TR?= MW\TRW5ITVJ?
KARPAS-45 M4LnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXpS|A5UUN3ME2wMlA4QDF3IN88US=> NGD1dmlUSU6JRWK=
EW-3 M{nTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEiwOVMh|ryP NFO1ZXBUSU6JRWK=
NB13 NFHsRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL6SWZFUUN3ME2wMlA5OjB|IN88US=> M3rYR3NCVkeHUh?=
NCI-H209 M4\EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEi3NFQh|ryP NEL1emxUSU6JRWK=
NCI-H1092 NGHTSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMUCyO|Uh|ryP NFv4VFZUSU6JRWK=
NH-12 NU\JUHNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUC3OFQh|ryP M4TxOHNCVkeHUh?=
697 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[4dHhKSzVyPUCuNVA5OzlizszN MVXTRW5ITVJ?
KE-37 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5UYRKSzVyPUCuNVE{PyEQvF2= M3PWc3NCVkeHUh?=
MOLT-4 NVjYbm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLrPWV1UUN3ME2wMlE2OTZ7IN88US=> M{jxTXNCVkeHUh?=
CHP-134 M1;vTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnKN2hxUUN3ME2wMlE3OzB4IN88US=> NU[2ZnFIW0GQR1XS
D-283MED NVjSd2l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTYfWFKSzVyPUCuNVc3QDZizszN NUW4b21UW0GQR1XS
LU-135 NYr5bFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PmcmlEPTB;MD6xPFU2OiEQvF2= MXfTRW5ITVJ?
LU-134-A NXr2W4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\TXnJqUUN3ME2wMlE5PjdzIN88US=> Mn7YV2FPT0WU
EM-2 M1LMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH34[XNKSzVyPUCuNVk6OThizszN NVj5WIY5W0GQR1XS
LU-139 NELpR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMkC0PVgh|ryP M37pfHNCVkeHUh?=
ALL-PO NY\zXIxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\FTWM2OD1yLkKxPVg5KM7:TR?= M4f1cHNCVkeHUh?=
NB12 NWS4W4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMkOxNVUh|ryP NFfWdFZUSU6JRWK=
KP-N-YN NGLscnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P0TWlEPTB;MD6yN|U4OyEQvF2= NWjCbpZOW0GQR1XS
BEN M13IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED2Z|hKSzVyPUCuNlM6PjhizszN MoLiV2FPT0WU
HCC1569 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jYbWlEPTB;MD6yOVExPiEQvF2= NIPNW2NUSU6JRWK=
HuO9 NVz3VXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zvSGlEPTB;MD6yOlcyPSEQvF2= NFHRNYpUSU6JRWK=
WM-115 NX:2b3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTq[ZhIUUN3ME2wMlI4PzN6IN88US=> NVnvNYVvW0GQR1XS
CCRF-CEM MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvWS4FKSzVyPUCuN|M2OjlizszN MWrTRW5ITVJ?
IST-SL1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv6TWM2OD1yLkO1N|Q{KM7:TR?= M{ezPHNCVkeHUh?=
BE-13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS3TWM2OD1yLkO2OFU6KM7:TR?= MUHTRW5ITVJ?
COR-L88 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXziWGc5UUN3ME2wMlM3PTRizszN NVTtepk6W0GQR1XS
DOHH-2 M4G2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PyfGlEPTB;MD60NVAzOyEQvF2= MXrTRW5ITVJ?
A704 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwNEK2O{DPxE1? MWTTRW5ITVJ?
KNS-81-FD MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;3TWM2OD1yLkS0NFE4KM7:TR?= MXrTRW5ITVJ?
RPMI-8226 NW\ZPVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;KTWM2OD1yLkS1OlUzKM7:TR?= NYLzR|hNW0GQR1XS
TGBC24TKB MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M133WGlEPTB;MD60OVc4QCEQvF2= M1TvNHNCVkeHUh?=
NCI-H1304 M4\vTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XnNGlEPTB;MD60OlE2PyEQvF2= NHL6eFNUSU6JRWK=
MOLT-13 M4[3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfDZYhwUUN3ME2wMlQ3PjF|IN88US=> MYXTRW5ITVJ?
EW-22 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\3V3dKSzVyPUCuOFY3PzFizszN NFn2UHdUSU6JRWK=
MS-1 NUPSXlJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfWTWM2OD1yLkS2PVM{KM7:TR?= NXPROVQ3W0GQR1XS
RMG-I NIfWdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwNEm0OlQh|ryP NYPScJZ[W0GQR1XS
NTERA-S-cl-D1 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzOUmxKSzVyPUCuOVAxOTlizszN NXnW[nRjW0GQR1XS
NCI-H1048 NYXseIVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTzW2VDUUN3ME2wMlUxQTV|IN88US=> M2PVeHNCVkeHUh?=
SW1417 NUfwdG0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTwOJcxUUN3ME2wMlU2PDN6IN88US=> M4LJR3NCVkeHUh?=
DB NEjZVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ub5FKSzVyPUCuOVcxQCEQvF2= NFT6R5BUSU6JRWK=
MEG-01 NXT0SpNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHFRoNQUUN3ME2wMlU5OzJizszN M1PhTXNCVkeHUh?=
EW-13 NX3pem1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNUizOFEh|ryP NGrpWlZUSU6JRWK=
LAMA-84 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH1TWM2OD1yLkW5NlA4KM7:TR?= NHvZe4FUSU6JRWK=
J-RT3-T3-5 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2riNGlEPTB;MD62NFgxQCEQvF2= Mny1V2FPT0WU
MOLT-16 NYKyR2U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLpTWM2OD1yLk[1NlY1KM7:TR?= M1nzWnNCVkeHUh?=
DU-4475 NHT0O41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfiTWM2OD1yLk[1OFI4KM7:TR?= M4LFcXNCVkeHUh?=
HAL-01 NYX6ZmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq1T3hlUUN3ME2wMlczPTR7IN88US=> NGr5cWpUSU6JRWK=
RD NHPZTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXrenBKSzVyPUCuO|U5QTlizszN MmjxV2FPT0WU
OAW-28 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LhV2lEPTB;MD63PFM4KM7:TR?= MXrTRW5ITVJ?
HCC38 MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Wb|NtUUN3ME2wMlgxOTlizszN MnjDV2FPT0WU
NMC-G1 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPqSo83UUN3ME2wMlgyOTJzIN88US=> NImyOIxUSU6JRWK=
EW-16 NV6wTIhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MleyTWM2OD1yLkixN|I5KM7:TR?= MXfTRW5ITVJ?
DU-145 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfXOWhKSzVyPUCuPFk6OjNizszN NYewTXBoW0GQR1XS
HPAF-II MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGwTWM2OD1yLkmyOlI5KM7:TR?= MlO5V2FPT0WU
A427 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PyTGlEPTB;MD65N|AzOiEQvF2= MVvTRW5ITVJ?
PA-1 M3;OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGexcmtKSzVyPUCuPVU3PDJizszN M1PRT3NCVkeHUh?=
OAW-42 NW\MWGtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u4OGlEPTB;MD65OlE1PiEQvF2= M33T[3NCVkeHUh?=
L-428 M2CxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPVTWM2OD1zLkCxNlUh|ryP MlnDV2FPT0WU
COLO-824 NWjJ[YQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjtTWM2OD1zLkCxO|A5KM7:TR?= NGe1c29USU6JRWK=
P30-OHK M4qxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7FTWM2OD1zLkC0Olg5KM7:TR?= MU\TRW5ITVJ?
NCI-H2170 NVK0UpM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\s[4VNUUN3ME2xMlA3OjNizszN MlLZV2FPT0WU
HCC2998 M37kfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHXTWM2OD1zLkC3NVM2KM7:TR?= NFfTfJdUSU6JRWK=
NB14 NHvnUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LyS2lEPTB;MT6xN|c1QCEQvF2= NHT6NXhUSU6JRWK=
TGBC1TKB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3tcmFCUUN3ME2xMlE1OTV{IN88US=> NVzwZpBxW0GQR1XS
KP-N-YS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwMU[yN|Yh|ryP MYXTRW5ITVJ?
CAL-120 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C1ZmlEPTB;MT6xOlQzQSEQvF2= NUi3SVd3W0GQR1XS
SBC-1 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnyR4lUUUN3ME2xMlE6ODV|IN88US=> MWPTRW5ITVJ?
C32 M3XUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS0dYNVUUN3ME2xMlE6ODh6IN88US=> NGnzVGtUSU6JRWK=
HCC2157 NGPXdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\QNZZKSzVyPUGuNVk1QTRizszN MlvHV2FPT0WU
COLO-792 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PvTmlEPTB;MT6yNFA4OSEQvF2= MWjTRW5ITVJ?
ES7 NIe3Om5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwMke5OVEh|ryP MlS5V2FPT0WU
HEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVviNncxUUN3ME2xMlMyODJ7IN88US=> MorDV2FPT0WU
ES4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{S5PVgh|ryP M2LFTHNCVkeHUh?=
NCI-SNU-1 M3nwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwM{[1OVUh|ryP NFPhXZhUSU6JRWK=
MDA-MB-415 NH\MWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjr[HFCUUN3ME2xMlM5QDVizszN NYnnemlNW0GQR1XS
NCI-H2342 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTMN3dKSzVyPUGuOFAzPjlizszN NEnYRY5USU6JRWK=
NB69 M2LNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwNE[yO|Eh|ryP M2\yU3NCVkeHUh?=
D-247MG M1rlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGroNI1KSzVyPUGuOVEyOjJizszN MWHTRW5ITVJ?
SCC-4 NHrNS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nLdWlEPTB;MT61PVg5PyEQvF2= NXjzNIVTW0GQR1XS
HuH-7 M1TCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz0T5JSUUN3ME2xMlY4Ojl|IN88US=> MVrTRW5ITVJ?
A388 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2OWlEPTB;MT62PFczPCEQvF2= MXfTRW5ITVJ?
Calu-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jkR2lEPTB;MT63NFY6PyEQvF2= MXrTRW5ITVJ?
NCI-H1648 M1LZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm4dJFKSzVyPUGuO|E1OThizszN M1X0XnNCVkeHUh?=
NCI-H2052 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq4bphuUUN3ME2xMlczOjBzIN88US=> Ml\uV2FPT0WU
Ramos-2G6-4C10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwN{O2OVYh|ryP NEPUd4VUSU6JRWK=
DEL M1rXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7SNlFKSzVyPUGuO|Q3QTJizszN NHzVV2tUSU6JRWK=
SNU-423 NVe4RnZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrC[mdqUUN3ME2xMlc5OTV5IN88US=> NVzlflVmW0GQR1XS
COR-L23 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rncmlEPTB;MT63PVg4PCEQvF2= MkDTV2FPT0WU
OMC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD1zLki2NFE3KM7:TR?= NHLOPG9USU6JRWK=
EW-11 M4\Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNN|RKSzVyPUGuPVU3PTdizszN NWnE[lFPW0GQR1XS
HSC-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FfItOUUN3ME2xMlk3OzZ3IN88US=> MWDTRW5ITVJ?
MLMA NYrlVJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M174T2lEPTB;MT65OlY4PyEQvF2= M1j2XHNCVkeHUh?=
RCM-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL2TIVTUUN3ME2yMlAxOzl7IN88US=> MXHTRW5ITVJ?
MFE-280 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX0TWM2OD1{LkCyPFQ5KM7:TR?= MkXzV2FPT0WU
ES8 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TEOWlEPTB;Mj6yOVQ4OSEQvF2= MUfTRW5ITVJ?
TE-11 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nVTmlEPTB;Mj6yPVQ4OyEQvF2= NEXoV|lUSU6JRWK=
HuO-3N1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwNEi3PEDPxE1? MXPTRW5ITVJ?
MHH-NB-11 NHLVNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5S|lOUUN3ME2yMlUyOTV6IN88US=> M{jQPHNCVkeHUh?=
TGBC11TKB M{PY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInh[3pKSzVyPUKuOVc3QDFizszN MmL5V2FPT0WU
HOP-92 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX1cFZKSzVyPUKuOVg4PDNizszN NIn4XWFUSU6JRWK=
IGR-1 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUezNppWUUN3ME2yMlYzODN3IN88US=> M{TrdXNCVkeHUh?=
GOTO NI\3N3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml71TWM2OD1{Lk[1N|c4KM7:TR?= M4\WVnNCVkeHUh?=
NCI-H1650 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fEWGlEPTB;Mj63NlIyPSEQvF2= MkPFV2FPT0WU
NCI-H1581 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfrTWM2OD1{Lke5OlgyKM7:TR?= MUXTRW5ITVJ?
NCI-H2405 NIK3dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[xeGlEPTB;Mj64Nlc5OiEQvF2= NEnUbZdUSU6JRWK=
U-118-MG MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwOU[0PVEh|ryP NIHrdFdUSU6JRWK=
DoTc2-4510 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi2RlVKSzVyPUOuNFE1OTdizszN Mlf1V2FPT0WU
NCI-H596 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwMES5PVch|ryP NIi3VmRUSU6JRWK=
MPP-89 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwMEW2OlYh|ryP M1LQOHNCVkeHUh?=
GCIY NWXXN2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHX[lJKSzVyPUOuNlA1QTFizszN MVPTRW5ITVJ?
SW626 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FTWM2OD1|LkK0OVQ{KM7:TR?= NHPHW5BUSU6JRWK=
OCI-AML2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNwM{GyO|Ih|ryP M1ntdnNCVkeHUh?=
NBsusSR M1\tVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq1NoVKSzVyPUOuN|Q6OzhizszN NVnBV3pNW0GQR1XS
AN3-CA M1fyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfwTWM2OD1|LkS0NlM5KM7:TR?= NGDXXlNUSU6JRWK=
EFM-19 NGHROpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL5TWM2OD1|LkS4N|M6KM7:TR?= NHzyRWZUSU6JRWK=
RVH-421 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTNwNU[4O|ch|ryP MVHTRW5ITVJ?
5637 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnXTWM2OD1|Lk[xNVA{KM7:TR?= Mo\TV2FPT0WU
PANC-08-13 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\DWIpKSzVyPUOuOlM1PzJizszN MYTTRW5ITVJ?
H9 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYruR2VFUUN3ME2zMlY4OTR2IN88US=> Mm\BV2FPT0WU
KARPAS-299 NE[1PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHIVHhKSzVyPUOuOlc{PjFizszN NIDyfm9USU6JRWK=
TE-5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO4TWM2OD1|LkewO|A6KM7:TR?= M3LqOHNCVkeHUh?=
NOS-1 NHHU[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwN{m4N|Qh|ryP MVPTRW5ITVJ?
HH M{LZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf4T5VEUUN3ME2zMlg{QDZ6IN88US=> MmnzV2FPT0WU
769-P NEnQPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\mTWM2OD1|Lki5OVEh|ryP NF\BOVNUSU6JRWK=
CHP-212 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nzZWlEPTB;Mz65NlU1QSEQvF2= MUDTRW5ITVJ?
NCI-H82 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTqXVRDUUN3ME2zMlk2QTN4IN88US=> NY[zT5REW0GQR1XS
Mo-T MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwMESzNVIh|ryP NYL3UpcyW0GQR1XS
BB65-RCC NXfUTZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDtTWM2OD12LkC0N|k6KM7:TR?= MUjTRW5ITVJ?
SW1990 NIW5dFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DXWGlEPTB;ND6wOVkxQCEQvF2= NHfJW5lUSU6JRWK=
LK-2 M17z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M376NmlEPTB;ND6xNVI6OyEQvF2= NV3qZW1PW0GQR1XS
ES5 M{Luc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwMUO5PFUh|ryP NV;5ZW85W0GQR1XS
JVM-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwMUiyNlIh|ryP M1e1RXNCVkeHUh?=
RPMI-7951 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5TWM2OD12LkKyOFE{KM7:TR?= NUHuPJZnW0GQR1XS
Calu-6 NHLITXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTRwMke4PFEh|ryP NIKxcWpUSU6JRWK=
LC-2-ad Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ntWmlEPTB;ND6yPVU3QCEQvF2= NGfHcohUSU6JRWK=
SW954 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV65b4M6UUN3ME20MlI6PjZizszN NFrCdZdUSU6JRWK=
H-EMC-SS NVWwUpllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\2TWM2OD12LkOxPFMyKM7:TR?= MYfTRW5ITVJ?
ES3 MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPYTWM2OD12LkO1OFQyKM7:TR?= NYDaZWF{W0GQR1XS
no-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvSTWM2OD12LkO1OVU1KM7:TR?= NULyOoEzW0GQR1XS
LAN-6 NXO4VYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorvTWM2OD12LkS1NVg6KM7:TR?= Moj2V2FPT0WU
FTC-133 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwNUO5OUDPxE1? MXjTRW5ITVJ?
8505C NEjQUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\oTWM2OD12LkW0NlMh|ryP MlrhV2FPT0WU
SW620 NWDENZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rwWmlEPTB;ND61O|A2PyEQvF2= MVnTRW5ITVJ?
BCPAP NHrYeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3wVHRqUUN3ME20MlY{PDhzIN88US=> NWrzOWIyW0GQR1XS
SK-LU-1 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPEU3J5UUN3ME20MlY3ODh7IN88US=> NVfT[4JiW0GQR1XS
NCI-H1623 M1XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37yS2lEPTB;ND63NFIzQCEQvF2= MYHTRW5ITVJ?
C2BBe1 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TmeWlEPTB;ND63OFAxQCEQvF2= NHOwbGZUSU6JRWK=
GP5d MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwN{izPFgh|ryP M1zpVXNCVkeHUh?=
NB6 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HnOmlEPTB;ND64OlIxPCEQvF2= MmnxV2FPT0WU
MDA-MB-157 M1PhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;DcYZKSzVyPUSuPFg4PiEQvF2= NIHJS2tUSU6JRWK=
UMC-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofLTWM2OD12Lki4PVY1KM7:TR?= NGDCUnBUSU6JRWK=
HCC1419 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXONHo6UUN3ME20MlkxODZ|IN88US=> Mn6wV2FPT0WU
NCI-H2029 NXG1WWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rjb2lEPTB;ND65OFE5PSEQvF2= M3HRdXNCVkeHUh?=
LXF-289 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjoVIFKSzVyPUWuNFM4OTlizszN MVHTRW5ITVJ?
KINGS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTVwMEe3OFQh|ryP MVLTRW5ITVJ?
HD-MY-Z NYrWe2ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTVwMkO5Olkh|ryP MVjTRW5ITVJ?
ESS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrpSY9ZUUN3ME21MlI2PTl5IN88US=> M1S0S3NCVkeHUh?=
GI-1 M2jnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;U[2lEPTB;NT6yO|kzPiEQvF2= MoPYV2FPT0WU
RPMI-2650 NITqe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHTWM2OD13LkO2NVYh|ryP MYXTRW5ITVJ?
IA-LM MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uxS2lEPTB;NT6zPVg4OSEQvF2= Mm\WV2FPT0WU
KP-4 M1;IfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzWZ3lKSzVyPUWuOFY{OzRizszN NVXGfIQyW0GQR1XS
G-402 NFL6cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7nW4tEUUN3ME21MlUyQDZ3IN88US=> NUfXOFdEW0GQR1XS
OS-RC-2 M{PSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ibWlEPTB;NT61NlYxPCEQvF2= MkPFV2FPT0WU
NCI-H1155 M1v5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwNUS5OVUh|ryP NVLJXGNnW0GQR1XS
OE19 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjXTWM2OD13Lk[4OlI1KM7:TR?= NVG2enVXW0GQR1XS
U-2-OS M2nPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ziSGlEPTB;NT64PVAyOyEQvF2= M2LxXXNCVkeHUh?=
SCC-15 M2rOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHMTWM2OD13LkmzOlYzKM7:TR?= MX3TRW5ITVJ?
NCI-H630 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX2TWM2OD13Lkm5OFA1KM7:TR?= MXPTRW5ITVJ?
PFSK-1 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfCO4NKSzVyPU[uNFUzPTlizszN NUj4R3FXW0GQR1XS
NCI-H1770 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vl[WlEPTB;Nj6yNFg4PCEQvF2= MUPTRW5ITVJ?
SK-MEL-3 NYLPVpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DjSmlEPTB;Nj60NlkyPSEQvF2= NWCzO45vW0GQR1XS
LB1047-RCC NUj6Nmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH6TWM2OD14LkS3OlI2KM7:TR?= NGm2doNUSU6JRWK=
NCI-H446 M1uzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7QcXNyUUN3ME22MlYzQTJ3IN88US=> Mo\xV2FPT0WU
SW780 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTZwN{CxPFUh|ryP NETaSYdUSU6JRWK=
NEC8 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwN{[2N{DPxE1? MVnTRW5ITVJ?
NOMO-1 NVLQTGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfoTWM2OD14Lke4NVEyKM7:TR?= MULTRW5ITVJ?
COLO-668 NGrMVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXETWM2OD14Lki0N|g4KM7:TR?= M3Ox[HNCVkeHUh?=
MC116 NHj5[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\VTWM2OD14LkmzPFk4KM7:TR?= M4[4T3NCVkeHUh?=
HCC1937 NEmzeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3mO3RFUUN3ME22Mlk6OjVzIN88US=> NEO0N4tUSU6JRWK=
NCI-N87 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLlNoJLUUN3ME23MlE6Ojl|IN88US=> NWnXSnZZW0GQR1XS
COLO-320-HSR MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm3TWM2OD15LkKyO|M5KM7:TR?= MYDTRW5ITVJ?
HCC1806 NUXMS495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdwMk[wOFQh|ryP M{S2ZnNCVkeHUh?=
OVCAR-3 NES5dHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwM{OwN|gh|ryP MUfTRW5ITVJ?
NUGC-3 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS4d4V{UUN3ME23MlM6Pjl2IN88US=> MoO1V2FPT0WU
SW1783 NXnIbFlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PTXWlEPTB;Nz60N|E4PSEQvF2= NEWwOVNUSU6JRWK=
GCT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXjTWM2OD15LkW2PVA3KM7:TR?= NHzSPHVUSU6JRWK=
NCI-H2126 NYiw[o9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fZR2lEPTB;Nz63N|YzPSEQvF2= NH7UR|NUSU6JRWK=
MEL-HO NWnWcowyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZXWlEPTB;Nz63O|A2PCEQvF2= NGjCcI1USU6JRWK=
CAPAN-1 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni4TWM2OD15Lke3N|U4KM7:TR?= MXXTRW5ITVJ?
SW756 NEn3d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofTTWM2OD15Lke4N|M{KM7:TR?= MWrTRW5ITVJ?
SKG-IIIa M1zZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTlTWM2OD15LkixPFkzKM7:TR?= M1jVOXNCVkeHUh?=
HCE-T Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnZdG5pUUN3ME23Mlg4Pzh|IN88US=> M4m1WHNCVkeHUh?=
Ca-Ski NFj2PWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e2fmlEPTB;Nz65PVM5OyEQvF2= MWfTRW5ITVJ?
COLO-684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXMPVc6UUN3ME24MlAyQDF6IN88US=> NF\CXXdUSU6JRWK=
KYSE-70 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X2NWlEPTB;OD6wO|czQSEQvF2= M4DxVHNCVkeHUh?=
TI-73 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H5[WlEPTB;OD6yOVg2OSEQvF2= NVf0XFZuW0GQR1XS
BT-20 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXlTWM2OD16LkK2NFUzKM7:TR?= NGfxNZhUSU6JRWK=
MHH-ES-1 M4npO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPqTWM2OD16LkWxPFM1KM7:TR?= M1n2WnNCVkeHUh?=
TE-12 M1rDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\4ZmlEPTB;OD61PVk{OSEQvF2= MmHiV2FPT0WU
YH-13 NYD3W|hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRThwNkGwNFgh|ryP MoDFV2FPT0WU
SF126 M2PwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRThwOEO4OlUh|ryP M1z4OHNCVkeHUh?=
J82 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyTWM2OD16LkmwNFM5KM7:TR?= MWnTRW5ITVJ?
RCC10RGB NFfyWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThwOUm1OlEh|ryP NHnzcIxUSU6JRWK=
SK-UT-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jGXWlEPTB;OT6wOFk1PSEQvF2= NYL6XVJiW0GQR1XS
LB2241-RCC M1PzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnFVZhKSzVyPUmuNVkyOzdizszN M2LLdnNCVkeHUh?=
LB996-RCC MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[5[WlEPTB;OT6xPVg6KM7:TR?= MoniV2FPT0WU
EPLC-272H NXnYPFRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzF[YdKSzVyPUmuN|c3PTdizszN M3\3ZnNCVkeHUh?=
CTV-1 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[wTWM2OD17LkW2OVMzKM7:TR?= MnX3V2FPT0WU
HSC-2 M{DyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vCdWlEPTB;OT61O|U2KM7:TR?= NWDFSY15W0GQR1XS
SK-MEL-28 M13rNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQV|ZKSzVyPUmuOlE5QTNizszN NIPTWZdUSU6JRWK=
MMAC-SF MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTlwNki3OUDPxE1? NH;KWHpUSU6JRWK=
CP50-MEL-B MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXpTWM2OD17Lke1O|gzKM7:TR?= NWr2Wlh4W0GQR1XS
HT-1080 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnuWFlKSzVyPUmuO|c4OzlizszN MlzSV2FPT0WU
HEC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTrTWM2OD1zMD6zN|UzKM7:TR?= MY\TRW5ITVJ?
AGS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xUmJKSzVyPUGwMlM4PCEQvF2= NXjJUWZqW0GQR1XS
GAMG MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\UdWlEPTB;MUCuOVE3OiEQvF2= MUfTRW5ITVJ?
SW48 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQdFZDUUN3ME2xNE42OTh7IN88US=> M{\NZXNCVkeHUh?=
U031 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLCTWM2OD1zMD61PVA5KM7:TR?= MlnzV2FPT0WU
OVCAR-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\XTWM2OD1zMD62OFI6KM7:TR?= NYj4[|MzW0GQR1XS
SF295 NHP4SWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vHe2lEPTB;MUCuOlcxPCEQvF2= NWTPfW9FW0GQR1XS
BHT-101 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFyLkexO|ch|ryP NV3FSnVNW0GQR1XS
VMRC-RCZ MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFzLkOyNFEh|ryP NVy5doZpW0GQR1XS
ACHN NYjMUmhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S0fWlEPTB;MUGuOFIyOSEQvF2= MlPyV2FPT0WU
NCI-H526 NEPLPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFzLkWwOFMh|ryP M{\4bnNCVkeHUh?=
MN-60 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkWzPUDPxE1? NWnQWmZvW0GQR1XS
NCI-H2291 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfFeI5sUUN3ME2xNU42PDZ4IN88US=> MXTTRW5ITVJ?
SCC-25 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\NXmlEPTB;MUGuO|U2PiEQvF2= NFO5Wm1USU6JRWK=
SK-MEL-2 M{\Vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfTbZV4UUN3ME2xNU44PjN5IN88US=> Mn;sV2FPT0WU
SN12C NH\UTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf3TWM2OD1zMT65N|U2KM7:TR?= NF7HeFlUSU6JRWK=
NCI-H69 M2nvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkSyN|Qh|ryP M1\kdnNCVkeHUh?=
ME-180 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP1XW1KSzVyPUGyMlcxPTRizszN M{faRnNCVkeHUh?=
MC-IXC M4fB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf5TWM2OD1zMj63OVE5KM7:TR?= M4Tt[XNCVkeHUh?=
NCI-H2347 M1ra[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;3e3h4UUN3ME2xNk44PjF2IN88US=> NIWzeG1USU6JRWK=
M059J M3rPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBTWlKSzVyPUGyMlc4OjdizszN NWj5b4R[W0GQR1XS
A2058 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLCXVE5UUN3ME2xNk45PjhzIN88US=> MlLaV2FPT0WU
VA-ES-BJ MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj2NYZKSzVyPUGyMlg4QDVizszN MkXpV2FPT0WU
Ca9-22 NUnm[pkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1OZN1UUN3ME2xNk46PDVzIN88US=> MoXWV2FPT0WU
KNS-42 M{W4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDtd5R7UUN3ME2xNk46QTh2IN88US=> NX\lNVl2W0GQR1XS
LoVo NXW1OnptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHpb|hKSzVyPUGzMlI{OTNizszN NXH4d5RkW0GQR1XS
AM-38 M3Lme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvmTWM2OD1zMz6yOVY3KM7:TR?= MkP4V2FPT0WU
NB5 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLQTWM2OD1zMz6zO|UzKM7:TR?= MkD4V2FPT0WU
L-363 NE[0SZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq5VlZKSzVyPUGzMlQxOzNizszN MmnJV2FPT0WU
SK-MEL-30 NUfpTI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF2LkC2OFUh|ryP M2DQWXNCVkeHUh?=
NCI-H1563 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfuTWM2OD1zND62NFM6KM7:TR?= NV71TFlbW0GQR1XS
NCI-H2228 NHS4R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF2Lk[wO|ch|ryP NIHHclVUSU6JRWK=
MFM-223 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvjOHlWUUN3ME2xOU4yQDF|IN88US=> MlLzV2FPT0WU
LB831-BLC M3PtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm5TWM2OD1zNT6yO|Y4KM7:TR?= Mm\rV2FPT0WU
SW872 NGS5TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF3LkOwPFYh|ryP NUjQTpRFW0GQR1XS
NCI-H522 NF[xU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvObYtKSzVyPUG1MlM{ODZizszN MXnTRW5ITVJ?
EW-1 NVH4NWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ToTmlEPTB;MUWuOVQ3OiEQvF2= NVK5[ldlW0GQR1XS
HN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P0OmlEPTB;MUWuOVk1OiEQvF2= MnnFV2FPT0WU
SW837 M2jKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF3Lke4OFch|ryP NUjtboszW0GQR1XS
SCC-9 NV7UdmQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzCN2dKSzVyPUG1MlgyOTRizszN MX\TRW5ITVJ?
MKN7 NWO0Z2VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rnfmlEPTB;MUWuPVc{OiEQvF2= MXzTRW5ITVJ?
KYSE-410 NV71RYVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;oWI1KSzVyPUG2MlU6OSEQvF2= NFvhOoxUSU6JRWK=
SK-N-DZ Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme2TWM2OD1zNj62NVE3KM7:TR?= MnvIV2FPT0WU
COR-L105 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF4Lk[1Nlgh|ryP MYTTRW5ITVJ?
LB2518-MEL M3eydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLV3RKSzVyPUG2Mlg{QDlizszN MonVV2FPT0WU
OVCAR-4 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrYN5dKSzVyPUG2Mlg5PjJizszN MWXTRW5ITVJ?
TK10 NXP2cY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTQTWM2OD1zNj65OFc{KM7:TR?= NFPyZ|hUSU6JRWK=
KNS-62 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH5fFBKSzVyPUG2Mlk4PzdizszN M4fEVXNCVkeHUh?=
RPMI-8866 M17kSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPLTXdKSzVyPUG3MlE4OzJizszN M13QOXNCVkeHUh?=
HuP-T4 NEjDZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfuUWdKSzVyPUG3MlI1QTVizszN MXzTRW5ITVJ?
CGTH-W-1 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K1T2lEPTB;MUeuOVIyQSEQvF2= NEPWNHhUSU6JRWK=
T-24 M36weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF5LkWzOFch|ryP M{KyWHNCVkeHUh?=
HT-3 NF:4e41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7CT4ZKSzVyPUG3MlU6OTRizszN M3PEV3NCVkeHUh?=
KS-1 NGnLV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nUPWlEPTB;MUeuOlc{KM7:TR?= NFXGcJFUSU6JRWK=
NCI-H1792 M2frU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDROXNKSzVyPUG3Mlc6QCEQvF2= MW\TRW5ITVJ?
ABC-1 NXfEbJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3yNYlKSzVyPUG3MlgyPDFizszN NE\X[HZUSU6JRWK=
BPH-1 M2XUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPaVYRKSzVyPUG4MlE3QDVizszN M{jtPXNCVkeHUh?=
A431 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnXUopKSzVyPUG4MlQyOjdizszN Ml21V2FPT0WU
T98G NFHCSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TvVmlEPTB;MUiuOVE2PyEQvF2= M1rGfnNCVkeHUh?=
BHY Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjFZ5BKSzVyPUG4Mlg3QSEQvF2= NELaPIlUSU6JRWK=
Capan-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XZeGlEPTB;MUiuPVA4QCEQvF2= M3TyUHNCVkeHUh?=
MDA-MB-175-VII M2CwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTERZNIUUN3ME2xPE46OjB7IN88US=> NIfEe4hUSU6JRWK=
CAL-27 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF7LkC0PFch|ryP NEHr[2xUSU6JRWK=
AsPC-1 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1zOT64OlU4KM7:TR?= M{ixWnNCVkeHUh?=
KU812 NGrIW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LqemlEPTB;MUmuPVU4OyEQvF2= M3zHPXNCVkeHUh?=
NCI-H441 NULQOIRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;WbJhKSzVyPUKwMlAxOSEQvF2= NWeyeZVLW0GQR1XS
Mewo MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkThTWM2OD1{MD6xNlg5KM7:TR?= NXnFPGNJW0GQR1XS
SK-MEL-24 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TUWmlEPTB;MkCuNVQ4PyEQvF2= NHHScoZUSU6JRWK=
NCI-H727 NUO5UmlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\LV2NKSzVyPUKwMlI4ODRizszN NIfBd5ZUSU6JRWK=
EKVX Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPvSnBoUUN3ME2yNE43ODZizszN Mn\lV2FPT0WU
RT-112 M{frOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvlSWNlUUN3ME2yNE43OTJ{IN88US=> M1q4NXNCVkeHUh?=
CAMA-1 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJyLkm4NFMh|ryP NYTPXWlGW0GQR1XS
SW900 NU[xSJpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7PZooyUUN3ME2yNU4xOTR7IN88US=> MnyxV2FPT0WU
NCI-H23 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWzd4dGUUN3ME2yNU4yOjd5IN88US=> M{DtN3NCVkeHUh?=
SK-PN-DW NFLCR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzEbItQUUN3ME2yNU4yPjR7IN88US=> NGDRZlhUSU6JRWK=
BB30-HNC NXH5RYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nleWlEPTB;MkGuNlc1PSEQvF2= NEDWfWFUSU6JRWK=
VM-CUB-1 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O2UWlEPTB;MkGuN|U{PiEQvF2= MknYV2FPT0WU
IST-MEL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXHTWM2OD1{MT6zOlkzKM7:TR?= NEe5WohUSU6JRWK=
CTB-1 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJzLkS3OVUh|ryP MmDCV2FPT0WU
LCLC-103H M{ezdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[ySG5KSzVyPUKyMlE2QDJizszN NF3FV3pUSU6JRWK=
PANC-03-27 M3;mPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ{LkWxOlkh|ryP MXHTRW5ITVJ?
HTC-C3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETlVXBKSzVyPUKyMlU2PTVizszN NF;LVVZUSU6JRWK=
TE-8 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT1OJNnUUN3ME2yN{4zPTZ3IN88US=> MXLTRW5ITVJ?
NCI-H292 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTuTWM2OD1{NT6zOVM3KM7:TR?= NWXGeJNKW0GQR1XS
COLO-680N MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4SydmlEPTB;MkWuOlMzQSEQvF2= M1vM[HNCVkeHUh?=
KYSE-520 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj4TWM2OD1{NT62OFQh|ryP MlzhV2FPT0WU
NB10 NEmwfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3EOoNYUUN3ME2yOk4{OTF5IN88US=> M4S1e3NCVkeHUh?=
NCI-H661 M{O2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ4LkS3NVMh|ryP NUXSdnROW0GQR1XS
GMS-10 NUTwUWk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe5TWM2OD1{Nj64OlM5KM7:TR?= MWjTRW5ITVJ?
NCI-H2122 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\NTWM2OD1{Nj65PVk5KM7:TR?= MUfTRW5ITVJ?
OVCAR-8 NV\UcGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ5LkC2N|gh|ryP NInub3ZUSU6JRWK=
DJM-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ5LkG0OVQh|ryP M2LWNnNCVkeHUh?=
UACC-893 NXTySoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\WRm9KSzVyPUK3Mlk5PzhizszN NE\RcFZUSU6JRWK=
C8166 NXuwNlBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3icmhKSzVyPUK4MlY6OzhizszN NETvOZpUSU6JRWK=
NCI-H1693 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rFemlEPTB;MkiuOlk4PSEQvF2= MYPTRW5ITVJ?
TYK-nu MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNyLkCzOFUh|ryP NGrzU4hUSU6JRWK=
SW1710 NUXrUpFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvPWFVkUUN3ME2zNE4yOjZizszN NFPVdWNUSU6JRWK=
A375 M1\ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXp[XhvUUN3ME2zNE4{OjR|IN88US=> NIXxeJNUSU6JRWK=
HMV-II NX;rZ|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNzLkO1PVIh|ryP M1zRWnNCVkeHUh?=
NCI-H2087 NXrFRnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNzLk[zOVIh|ryP NFXiS4hUSU6JRWK=
CAL-54 M{\NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D1TWlEPTB;M{GuO|I1OSEQvF2= NXnXO5ZPW0GQR1XS
HCC70 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN{LkGzPFch|ryP NVnmXnVvW0GQR1XS
ES1 NYT3UFljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN{LkOwOlIh|ryP NHrNW2hUSU6JRWK=
NCI-H1355 M3XDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX3TWM2OD1|Mz6yNFQh|ryP NXfrcZNLW0GQR1XS
CFPAC-1 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5epduUUN3ME2zN{4zOzN{IN88US=> NIPOfFFUSU6JRWK=
MKN28 M1\UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG0bYlUUUN3ME2zN{4{QDB7IN88US=> NHj0dIhUSU6JRWK=
HDLM-2 NXTQ[5pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTN|Lk[5N|Eh|ryP NYX0SoJxW0GQR1XS
PANC-10-05 M1XhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTWeVFSUUN3ME2zOE4yODF2IN88US=> NFjx[pdUSU6JRWK=
SAS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN2LkS1OlUh|ryP NVHLTXRGW0GQR1XS
HCC1395 NIr4WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TJV2lEPTB;M{SuO|E5PiEQvF2= M2HyNnNCVkeHUh?=
8305C M4ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN3Lki0NVUh|ryP NGiyXW5USU6JRWK=
KM12 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN4Lke1OFch|ryP NWrQ[m1nW0GQR1XS
SW1116 M{X3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTN5LkW5PVIh|ryP M2GzT3NCVkeHUh?=
SK-MEL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW5Z4s4UUN3ME2zPE4{Ozh7IN88US=> NXjaTmNwW0GQR1XS
HCC2218 M2\mcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j6VmlEPTB;M{iuOlUyQSEQvF2= NWHBNW1IW0GQR1XS
T84 NYSwSIF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dje2lEPTB;M{iuO|QxQSEQvF2= MXTTRW5ITVJ?
ETK-1 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M324[GlEPTB;M{muNFIzKM7:TR?= NF73[ohUSU6JRWK=
COLO-800 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn0Z|NKSzVyPUO5MlM5PjhizszN NV7Vb2o3W0GQR1XS
CAL-12T NVXsXnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TyemlEPTB;M{muOVI5OSEQvF2= MYHTRW5ITVJ?
ACN NWroSGprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOyZotKSzVyPUSwMlQ6OTFizszN MU\TRW5ITVJ?
SJSA-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\idVJvUUN3ME20NU4yPTl4IN88US=> NEnBWJRUSU6JRWK=
PSN1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRzLkG3OFkh|ryP Ml\5V2FPT0WU
D-566MG MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRzLkKwPFYh|ryP NFjaO4lUSU6JRWK=
EGI-1 M2L0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTJSol3UUN3ME20Nk41OjhizszN MYfTRW5ITVJ?
A204 NYLrV3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOzTWM2OD12Mj62N|g5KM7:TR?= Mn7BV2FPT0WU
Saos-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\HTWM2OD12Mj64N|Y6KM7:TR?= MmTrV2FPT0WU
SNU-C2B NH3BSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHpcZhKSzVyPUSzMlY5PzhizszN Mmr4V2FPT0WU
HLE M3rr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn5TWM2OD12ND6wPFU3KM7:TR?= MXjTRW5ITVJ?
SW1463 M1rn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPQTXFKSzVyPUS0Mlk6PzFizszN NWLzO45WW0GQR1XS
DSH1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lrc2lEPTB;NEWuNFA{OyEQvF2= NELYWo9USU6JRWK=
MCF7 NWTUcW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme1TWM2OD12NT61NFUyKM7:TR?= Ml23V2FPT0WU
K5 NYLFTGt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:5TWM2OD12NT65OFA2KM7:TR?= NGTtZpVUSU6JRWK=
NCI-H358 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\1SmlEPTB;NEeuNlE2KM7:TR?= NHzlUGpUSU6JRWK=
NCI-H2030 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD12Nz6yN|c1KM7:TR?= MmPHV2FPT0WU
SW948 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfuOZZKSzVyPUS3MlQ3PCEQvF2= MmXnV2FPT0WU
BALL-1 M1HYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W0NWlEPTB;NEeuOlE3QCEQvF2= M3OweHNCVkeHUh?=
TE-9 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTR5Lkm1PFEh|ryP NITZe25USU6JRWK=
SK-N-FI NXr5TmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLKTWM2OD12OD6wN|U5KM7:TR?= NGr6SZdUSU6JRWK=
KALS-1 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTtXlY2UUN3ME20PE4yOjh7IN88US=> MnXqV2FPT0WU
HO-1-N-1 NGHIbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqxR5lKSzVyPUS4Mlc1PDVizszN NVu4XoQxW0GQR1XS
NCI-H2452 M3T0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDMUnNKSzVyPUS5MlEyPTJizszN NWLM[mtNW0GQR1XS
OC-314 M13oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj2empKSzVyPUS5MlY5OzRizszN NX20N5V6W0GQR1XS

... Click to View More Cell Line Experimental Data
体内研究 用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
+ 展开

激酶实验:

用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验：

[1]
+ 展开
  • Cell lines: SCLC 细胞系
  • Concentrations: 0-1 μM
  • Incubation Time: 48小时
  • Method:

    人类肿瘤细胞系在37oC 含5% CO2环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。


    (Only for Reference)
动物实验：

[1]
+ 展开
  • Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠
  • Formulation: ABT-263在10% 乙醇, 30% 聚乙二醇400, 及60% Phosal 50 PG中制成
  • Dosages: 100 mg/kg/d
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+corn oil 		7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 974.61
化学式

C47H55ClF3N5O6S3
CAS号 923564-51-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1
NCT02079740 Recruiting Advanced Malignant Solid Neoplasm|KRAS Gene Mutation|Metastatic Malignant Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Malignant Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • 回答：

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • 问题 2：

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • 回答：

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Selleck产品目录册

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

  • 选择性强的Bcl-2抑制剂

    ABT-199 (GDC-0199) : Bcl-2-selective, Ki<0.01 nM.

  • 用于临床的Bcl-2抑制剂

    Obatoclax Mesylate (GX15-070) ： Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • 最新的Bcl-2家族激活剂

    BAM7 ： Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • 经典的Bcl-2抑制剂

    ABT-737 ： BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

相关Bcl-2产品

  • A-1210477 New

    A-1210477是一种有效的选择性MCL-1抑制剂，Ki和IC50分别为0.454 nM 和 26.2 nM，选择性比作用于其他Bcl-2家族成员高100多倍。

  • MI-773 (SAR405838) New

    MI-773 (SAR405838) 是一种口服生物有效的MDM2拮抗剂，Ki为0.88 nM。Phase 1。

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂，无细胞试验中Ki为<0.01 nM，比作用于Bcl-xL和Bcl-w选择性高4800倍以上，对Mcl-1没有抑制活性。Phase 3。

    Features:ABT-263 (Navitoclax)的重组

  • ABT-737

    ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。Phase 2。

    Features:ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

  • UMI-77

    UMI-77是一种选择性Mcl-1抑制剂，Ki为490 nM，表现出高于Bcl-2家族其它成员的选择性。

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)是一种Bcl-2拮抗剂，无细胞试验中Ki为0.22 μM，可以协助抑制MCL-1介导的抗细胞凋亡作用。Phase 3。

    Features:Obatoclax是有应用前景的小分子Bcl-2拮抗剂，抑制Bcl-2蛋白家族所有相关的膜结构，包括 Mcl-1。

  • TW-37

    TW-37是一种新型的非肽类抑制剂，作用于重组Bcl-2，Bcl-xL和Mcl-1，无细胞试验中Ki分别为0.29 μM， 1.11 μM和0.26 μM。

    Features:TW-37是新型非肽类小分子 Bcl-2抑制剂。

  • Sabutoclax

    Sabutoclax是一种pan-Bcl-2抑制剂，作用于Bcl-xL， Bcl-2， Mcl-1和Bfl-1，IC50分别为0.31 μM， 0.32 μM， 0.20 μM和0.62 μM。

  • AT101

    AT101，是醋酸棉酚的R-(-)对映体，与Bcl-2，Bcl-xL和Mcl-1结合，无细胞试验中Ki为0.32 μM，0.48 μM 和 0.18 μM；不抑制BIR3域和BID。Phase 2。

Tags: 购买Navitoclax (ABT-263) | Navitoclax (ABT-263)供应商 | 采购Navitoclax (ABT-263) | Navitoclax (ABT-263)价格 | Navitoclax (ABT-263)生产 | 订购Navitoclax (ABT-263) | Navitoclax (ABT-263)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID